Litcius/Paper detail

LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO

Chiara Cremolini, Daniele Rossini, Carlotta Antoniotti, Filippo Pietrantonio, Sara Lonardi, Lisa Salvatore, Federica Marmorino, Beatrice Borelli, Margherita Ambrosini, Giulia Barsotti, B. Di Stefano, Gianluca Masi, Alessandra Boccaccino, Stefano Tamberi, Emiliano Tamburini, L.G. Frassineti, Francesca Simionato, Gabriella Fontanini, Luca Boni, Alfredo Falcone

2021Annals of Oncology32 citationsDOI

Topics & Concepts

MedicineAtezolizumabBevacizumabColorectal cancerInternal medicineOncologyRandomized controlled trialFirst line treatmentCancerChemotherapyNivolumabImmunotherapyColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research
LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO | Litcius